Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Liabilities: 2019-2024

Historic Total Liabilities for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $370.3 million.

  • Beam Therapeutics' Total Liabilities fell 9.20% to $345.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.1 million, marking a year-over-year decrease of 9.20%. This contributed to the annual value of $370.3 million for FY2024, which is 22.60% down from last year.
  • Per Beam Therapeutics' latest filing, its Total Liabilities stood at $370.3 million for FY2024, which was down 22.60% from $478.4 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Total Liabilities registered a high of $647.7 million during FY2021, and its lowest value of $206.1 million during FY2020.
  • Over the past 3 years, Beam Therapeutics' median Total Liabilities value was $478.4 million (recorded in 2023), while the average stood at $485.6 million.
  • Per our database at Business Quant, Beam Therapeutics' Total Liabilities soared by 273.71% in 2020 and then dropped by 22.60% in 2024.
  • Over the past 5 years, Beam Therapeutics' Total Liabilities (Yearly) stood at $206.1 million in 2020, then surged by 214.25% to $647.7 million in 2021, then declined by 6.09% to $608.2 million in 2022, then fell by 21.35% to $478.4 million in 2023, then fell by 22.60% to $370.3 million in 2024.